203 related articles for article (PubMed ID: 33566242)
1. Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence.
Nakauchi M; Vos E; Tang LH; Gonen M; Janjigian YY; Ku GY; Ilson DH; Maron SB; Yoon SS; Brennan MF; Coit DG; Strong VE
Ann Surg Oncol; 2021 Sep; 28(9):4829-4838. PubMed ID: 33566242
[TBL] [Abstract][Full Text] [Related]
2. ypTNM staging is a potentially useful prognostic stratification tool in patients with advanced gastric cancer after preoperative chemotherapy.
Otsuka R; Hayano K; Hayashi H; Uesato M; Murakami K; Toyozumi T; Matsumoto Y; Kurata Y; Nakano A; Matsubara H
Langenbecks Arch Surg; 2023 Mar; 408(1):133. PubMed ID: 37000278
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
Peng L; Yang W; Zhang Z; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
[TBL] [Abstract][Full Text] [Related]
4. Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
Ruf C; Thomusch O; Goos M; Makowiec F; Illerhaus G; Ruf G
BMC Surg; 2014 Jan; 14():5. PubMed ID: 24461063
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy.
Ikoma N; Chen HC; Wang X; Blum M; Estrella JS; Fournier K; Mansfield P; Ajani J; Badgwell BD
Ann Surg Oncol; 2017 Sep; 24(9):2679-2687. PubMed ID: 28332034
[TBL] [Abstract][Full Text] [Related]
6. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
7. Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer.
Erstad DJ; Blum M; Estrella JS; Das P; Minsky BD; Ajani JA; Mansfield PF; Badgwell BD; Ikoma N
Ann Surg Oncol; 2021 Oct; 28(11):6638-6648. PubMed ID: 33754224
[TBL] [Abstract][Full Text] [Related]
8. Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy.
Takahashi R; Ohashi M; Kano Y; Ida S; Kumagai K; Nunobe S; Chin K; Yamaguchi K; Nagino M; Sano T; Hiki N
Gastric Cancer; 2019 Nov; 22(6):1256-1262. PubMed ID: 30877407
[TBL] [Abstract][Full Text] [Related]
9. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study.
Mokadem I; Dijksterhuis WPM; van Putten M; Heuthorst L; de Vos-Geelen JM; Haj Mohammad N; Nieuwenhuijzen GAP; van Laarhoven HWM; Verhoeven RHA
Gastric Cancer; 2019 Nov; 22(6):1263-1273. PubMed ID: 30949777
[TBL] [Abstract][Full Text] [Related]
10. Monthly tegafur-uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study.
Kuo YH; Lai CH; Huang CY; Chen CJ; Huang YC; Huang WS; Chin CC
BMC Cancer; 2019 Aug; 19(1):815. PubMed ID: 31419963
[TBL] [Abstract][Full Text] [Related]
11. [Is Adjuvant Chemotherapy Necessary after R0 Resection for pCR or ypStage I Patients with Gastric Cancer ?].
Yamamoto K; Nishikawa K; Hirao M; Fujitani K; Tsujinaka T; Uemura M; Miyake M; Hama N; Miyamoto A; Miyazaki M; Omiya H; Ikeda M; Takami K; Nakamori S; Sekimoto M
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1929-1932. PubMed ID: 28133179
[TBL] [Abstract][Full Text] [Related]
12. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
[TBL] [Abstract][Full Text] [Related]
13. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study.
Kim HD; Lee JS; Park YS; Yook JH; Noh SH; Park YK; Kim YW; Oh SC; Kim JG; Ryu MH; Cheong JH; Kim H; Lim JS; Lee JH; Heo SH; Kim JY; Heo MH; Park YI; Kim IH; Kang YK
Gastric Cancer; 2022 Nov; 25(6):1039-1049. PubMed ID: 35920999
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
Kosaka T; Akiyama H; Miyamoto H; Sato S; Tanaka Y; Sato K; Kunisaki C; Endo I
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1047-1055. PubMed ID: 30911769
[TBL] [Abstract][Full Text] [Related]
15. [Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].
Wang TB; Mao QK; Zhang XJ; Zhou H; Guo CG; Chen YT; Zhao DB
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):160-166. PubMed ID: 33508922
[No Abstract] [Full Text] [Related]
16. Factors associated with early recurrence after curative surgery for gastric cancer.
Kang WM; Meng QB; Yu JC; Ma ZQ; Li ZT
World J Gastroenterol; 2015 May; 21(19):5934-40. PubMed ID: 26019458
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A
Ann Surg Oncol; 2012 May; 19(5):1568-74. PubMed ID: 22143578
[TBL] [Abstract][Full Text] [Related]
18. The patterns and timing of recurrence after curative resection for gastric cancer in China.
Liu D; Lu M; Li J; Yang Z; Feng Q; Zhou M; Zhang Z; Shen L
World J Surg Oncol; 2016 Dec; 14(1):305. PubMed ID: 27931221
[TBL] [Abstract][Full Text] [Related]
19. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.
Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y
Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
